2020 Q4 Form 10-Q Financial Statement

#000121390020037061 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $148.3K $153.2K $150.0K
YoY Change -12.75%
Operating Profit
YoY Change
Interest Expense $34.42K $44.05K $20.00K
YoY Change -88.53%
% of Operating Profit
Other Income/Expense, Net -$1.975M -$197.5K
YoY Change
Pretax Income -$2.089M -$109.2K -$130.0K
YoY Change -1706.97%
Income Tax -$23.92K -$22.87K -$30.00K
% Of Pretax Income
Net Earnings -$2.065M -$86.31K -$98.97K
YoY Change -2165.14% 99104.6% 29093.51%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$125.8K -$17.34K -$0.12
COMMON SHARES
Basic Shares Outstanding 16.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.9M $130.9M $300.0K
YoY Change 0.14%
Cash & Equivalents $171.5K $242.9K
Short-Term Investments $130.7M $130.6M
Other Short-Term Assets $99.74K $139.0K $200.0K
YoY Change -50.13%
Inventory
Prepaid Expenses $99.74K $139.0K
Receivables
Other Receivables
Total Short-Term Assets $271.3K $381.9K $500.0K
YoY Change -49.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $130.7M $130.6M $130.6M
YoY Change 0.29%
Other Assets $540.00 $0.00
YoY Change -99.46%
Total Long-Term Assets $130.7M $130.6M $130.6M
YoY Change 0.28% 130547.17%
TOTAL ASSETS
Total Short-Term Assets $271.3K $381.9K $500.0K
Total Long-Term Assets $130.7M $130.6M $130.6M
Total Assets $131.0M $131.0M $131.1M
YoY Change 0.08% 130929.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.0K $110.1K
YoY Change
Accrued Expenses $100.0K
YoY Change
Deferred Revenue $1.585M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $170.5K $157.7K $100.0K
YoY Change -0.07% 57.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.950M
YoY Change
Total Long-Term Liabilities $3.950M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $170.5K $157.7K $100.0K
Total Long-Term Liabilities $3.950M $0.00 $0.00
Total Liabilities $4.121M $157.7K $100.0K
YoY Change 2314.75% 57.7%
SHAREHOLDERS EQUITY
Retained Earnings -$3.714M $292.6K
YoY Change -3759.26%
Common Stock $337.00 $383.00
YoY Change -11.78% 7.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.069M $5.000M $5.000M
YoY Change
Total Liabilities & Shareholders Equity $131.0M $131.0M $131.1M
YoY Change 0.08% 130929.06%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$2.065M -$86.31K -$98.97K
YoY Change -2165.14% 99104.6% 29093.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$71.35K -$539.6K -$140.0K
YoY Change -67.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $419.9K $40.00K
YoY Change -100.0%
Cash From Investing Activities $0.00 $419.9K $40.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -71.35K -539.6K -140.0K
Cash From Investing Activities 0.000 419.9K 40.00K
Cash From Financing Activities
Net Change In Cash -71.35K -119.7K -100.0K
YoY Change -120.39% -1296.8%
FREE CASH FLOW
Cash From Operating Activities -$71.35K -$539.6K -$140.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Class Of Warrant Or Right Expense Or Revenue Recognized
ClassOfWarrantOrRightExpenseOrRevenueRecognized
● in whole and not in part; ● at a price of $0.01 per warrant; ● upon not less than 30 days' prior written notice of redemption; ● if, and only if, the reported last sale price of the Company's common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third business day prior to the notice of redemption to the warrant holders; and ● If, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying the warrants.
dei Entity Central Index Key
EntityCentralIndexKey
0001785592
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
Merida Merger Corp. I
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
USD
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
130646624 USD
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16371940 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
242895 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362570 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
138999 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
176869 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
381894 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
539439 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
544 USD
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
130311535 USD
CY2020Q3 us-gaap Assets
Assets
131029062 USD
CY2019Q4 us-gaap Assets
Assets
130850974 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
110127 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
126891 USD
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
30778 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
26934 USD
CY2020Q3 MCMJ Advances From Related Party
AdvancesFromRelatedParty
16458 USD
CY2019Q4 MCMJ Advances From Related Party
AdvancesFromRelatedParty
16458 USD
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
339 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
339 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
157702 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
170622 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
48 USD
CY2020Q3 us-gaap Liabilities
Liabilities
157702 USD
CY2019Q4 us-gaap Liabilities
Liabilities
170670 USD
CY2020Q3 MCMJ Temporary Equity Common Stock Possible To Redemption Shares
TemporaryEquityCommonStockPossibleToRedemptionShares
12537714 shares
CY2019Q4 MCMJ Temporary Equity Common Stock Possible To Redemption Shares
TemporaryEquityCommonStockPossibleToRedemptionShares
12550477 shares
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
125871358 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
125680303 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3834226 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3834226 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
383 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
382 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4707061 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4898117 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
292558 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
101502 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5000002 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000001 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131029062 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130850974 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-426 USD
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
42577 USD
CY2020Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
153230 USD
CY2019Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
87 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-512896 USD
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
USD
us-gaap Interest And Other Income
InterestAndOtherIncome
757577 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
USD
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1474 USD
CY2019Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2594 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
44051 USD
CY2019Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
754983 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109179 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
242087 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22871 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51031 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-86308 USD
us-gaap Net Income Loss
NetIncomeLoss
-426 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3826395 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3120000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3821429 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3120000 shares
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000001 USD
CY2020Q1 MCMJ Stock Issued During Period Value Common Stock Subject To Possible Redemption
StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption
-376321 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
376330 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5000010 USD
CY2020Q2 MCMJ Stock Issued During Period Value Common Stock Subject To Possible Redemption
StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption
98960 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-98966 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5000004 USD
CY2020Q3 MCMJ Stock Issued During Period Value Common Stock Subject To Possible Redemption
StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption
86306 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5000002 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
USD
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
910 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-339 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
25571 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-87 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
25484 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
MCMJ Shares Subject To Forfeiture
SharesSubjectToForfeiture
199612 shares
CY2019Q4 MCMJ Stock Dividend
StockDividend
0.2
us-gaap Net Income Loss
NetIncomeLoss
191056 USD
us-gaap Net Income Loss
NetIncomeLoss
-426 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
757577 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2594 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-592 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-37870 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16764 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3844 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-539569 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-426 USD
MCMJ Cash Withdrawn From Trust Account To Pay Franchise Taxes
CashWithdrawnFromTrustAccountToPayFranchiseTaxes
419894 USD
MCMJ Cash Withdrawn From Trust Account To Pay Franchise Taxes
CashWithdrawnFromTrustAccountToPayFranchiseTaxes
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
419894 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
75569 USD
MCMJ Payment Of Offering Costs
PaymentOfOfferingCosts
USD
MCMJ Payment Of Offering Costs
PaymentOfOfferingCosts
-65480 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10089 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-119675 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9663 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362570 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
242895 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9663 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
47779 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
MCMJ Change In Value Of Common Stock Subject To Possible Redemption
ChangeInValueOfCommonStockSubjectToPossibleRedemption
191055 USD
MCMJ Change In Value Of Common Stock Subject To Possible Redemption
ChangeInValueOfCommonStockSubjectToPossibleRedemption
USD
MCMJ Issuance Of Representative Shares
IssuanceOfRepresentativeShares
USD
MCMJ Issuance Of Representative Shares
IssuanceOfRepresentativeShares
910 USD
MCMJ Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
5000 USD
MCMJ Deferred Offering Cost Paid Directly By Stockholder In Consideration For Issuance Of Common Stock
DeferredOfferingCostPaidDirectlyByStockholderInConsiderationForIssuanceOfCommonStock
USD
MCMJ Deferred Offering Cost Paid Directly By Stockholder In Consideration For Issuance Of Common Stock
DeferredOfferingCostPaidDirectlyByStockholderInConsiderationForIssuanceOfCommonStock
25000 USD
us-gaap Nature Of Operations
NatureOfOperations
<p class="noteheader" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-weight:bold;">Note 1 — Description of Organization and Business Operations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Merida Merger Corp. I (the "Company") was incorporated in Delaware on <span class="wrapped oz-date">June 20, 2019</span>. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (the "Business Combination").</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus its search on companies in the cannabis industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of <span class="wrapped oz-date">September 30, 2020</span>, the Company had not commenced any operations. All activity through <span class="wrapped oz-date">September 30, 2020</span> relates to the Company's formation, the IPO ("IPO"), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The registration statements for the Company's IPO were declared effective on <span class="wrapped oz-date">November 4, 2019</span>. On <span class="wrapped oz-date">November 7, 2019</span>, the Company consummated the IPO of 12,000,000 units (the "Units" and, with respect to the shares of common stock included in the Units sold, the "Public Shares"), generating gross proceeds of $120,000,000, which is described in Note 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Simultaneously with the closing of the IPO, the Company consummated the sale of 3,750,000 warrants (the "Private Warrants") at a price of $1.00 per Private Warrant in a private placement to Merida Holdings, LLC and EarlyBirdCapital, Inc. ("EarlyBirdCapital"), generating gross proceeds of $3,750,000, which is described in Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Following the closing of the IPO on <span class="wrapped oz-date"><span class="wrapped oz-date">November 7, 2019</span></span>, an amount of $120,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in a trust account (the "Trust Account") and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of <span class="wrapped oz-date year">1940</span>, as amended (the "Investment Company Act"), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account to the Company's stockholders, as described below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">On <span class="wrapped oz-date">November 12, 2019</span>, the underwriters notified the Company of their intention to partially exercise their over-allotment option on <span class="wrapped oz-date">November 13, 2019</span>. As such, on <span class="wrapped oz-date"><span class="wrapped oz-date">November 13, 2019</span></span> the Company consummated the sale of an additional 1,001,552 Units, at $10.00 per Unit, and the sale of an additional 200,311 Private Warrants, at $1.00 per Private Warrant, generating total gross proceeds of $10,215,831. A total of $10,015,520 of the net proceeds was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $130,015,520.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Transaction costs amounted to $3,412,939 consisting of $2,600,311 of underwriting fees and $812,628 of other offering costs. In addition, as of <span class="wrapped oz-date">September 30, 2020</span>, there was $242,895 of cash held outside of the Trust Account and available for working capital purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company's management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination having an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding taxes payable on income earned on the Trust Account) at the time of the agreement to enter into an initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. Upon the closing of the IPO, management has agreed that an amount equal to at least $10.00 per Unit sold in the IPO, including the proceeds from the sale of the Private Warrants, will be held in a trust account ("Trust Account"), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company will provide its holders of the outstanding Public Shares (the "public stockholders") with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination in connection with a stockholder meeting called to approve the Business Combination. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations and up to $250,000 per 12-month period for working capital needs). There will be no redemption rights upon the completion of a Business Combination with respect to the Company's warrants. The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. The Company will, pursuant to its Amended and Restated Certificate of Incorporation (the "Amended and Restated Certificate of Incorporation"), offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules. The Company's Sponsor and EarlyBirdCapital have agreed to vote their Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and not to convert any shares in connection with a stockholder vote to approve a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don't vote at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares and any Public Shares held by it in connection with the completion of a Business Combination, (b) to waive its rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to consummate a Business Combination, and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation that would affect a public stockholders' ability to convert their shares in connection with a Business Combination or affect the substance or timing of the Company's obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company will have until <span class="wrapped oz-date">November 7, 2021</span> to consummate a Business Combination (the "Combination Period"). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company, divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)  as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining stockholders and the Company's board of directors, dissolve and liquidate, subject in each case to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">In order to protect the amounts held in the Trust Account, Merida Manager III LLC, the general partner of the Sponsor, has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company's indemnity of the underwriters of IPO against certain liabilities, including liabilities under the Securities Act of <span class="wrapped oz-date year">1933</span>, as amended (the "Securities Act"). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, Merida Manager III LLC will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that Merida Manager III LLC will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company's independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><b>Risks and Uncertainties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or closing of a business combination, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3412939 USD
MCMJ Business Combination Agreement Terms1
BusinessCombinationAgreementTerms1
The Company must complete a Business Combination having an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding taxes payable on income earned on the Trust Account) at the time of the agreement to enter into an initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. Upon the closing of the IPO, management has agreed that an amount equal to at least $10.00 per Unit sold in the IPO, including the proceeds from the sale of the Private Warrants, will be held in a trust account ("Trust Account"), located in the United States and invested only in U.S. government securities,
MCMJ Withdrawal Amount Of Working Capital Purposes On Annual Basis
WithdrawalAmountOfWorkingCapitalPurposesOnAnnualBasis
250000 USD
CY2020Q3 MCMJ Minimum Amount Of Net Tangible Assets To Complete Business Combination
MinimumAmountOfNetTangibleAssetsToCompleteBusinessCombination
5000001 USD
MCMJ Public Share Percentage
PublicSharePercentage
1 pure
MCMJ Business Combination Period
BusinessCombinationPeriod
2021-11-07
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-weight:bold;">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of the condensed financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2020Q3 MCMJ Class Of Warrant To Purchase Shares Of Common Stock
ClassOfWarrantToPurchaseSharesOfCommonStock
10451087 shares
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-87 USD
us-gaap Net Income Loss
NetIncomeLoss
191056 USD
us-gaap Net Income Loss
NetIncomeLoss
-426 USD
CY2020Q3 MCMJ Income Attributable To Shares Subject To Redemption
IncomeAttributableToSharesSubjectToRedemption
-25093 USD
CY2019Q3 MCMJ Income Attributable To Shares Subject To Redemption
IncomeAttributableToSharesSubjectToRedemption
USD
MCMJ Income Attributable To Shares Subject To Redemption
IncomeAttributableToSharesSubjectToRedemption
-560501 USD
MCMJ Income Attributable To Shares Subject To Redemption
IncomeAttributableToSharesSubjectToRedemption
USD
CY2020Q3 MCMJ Adjusted Net Loss
AdjustedNetLoss
-111401 USD
CY2019Q3 MCMJ Adjusted Net Loss
AdjustedNetLoss
-87 USD
MCMJ Adjusted Net Loss
AdjustedNetLoss
-369445 USD
MCMJ Adjusted Net Loss
AdjustedNetLoss
-426 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3826395 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3120000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3821429 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3120000 shares
us-gaap Debt Instrument Description
DebtInstrumentDescription
The Promissory Note was non-interest bearing and payable on the earlier of (i) September 30, 2020, (ii) the consummation of the IPO or (iii) the date on which the Company determined not to proceed with the IPO. As of December 31, 2019, the Company repaid $100,230 of amounts owed under the Promissory Note and $339 remained outstanding under the Promissory Note at September 30, 2020 and December 31, 2019.
CY2020Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
1500000 USD
CY2020Q3 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
1.00
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-weight:bold;">Concentration of Credit Risk</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2020Q3 MCMJ Federal Depository Insurance Coverage
FederalDepositoryInsuranceCoverage
250000 USD
CY2019Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
2875000 shares
CY2019Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 USD
CY2019Q4 MCMJ Stock Dividend Description
StockDividendDescription
the Company effected a stock dividend of 0.2 shares for each share outstanding,
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
the Founder Shares until, with respect to 50% of the Founder Shares, the earlier of one year after the consummation of a Business Combination and the date on which the closing price of the common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, until the one year after the consummation of a Business Combination,
us-gaap Costs And Expenses
CostsAndExpenses
162500 USD
CY2019Q4 us-gaap Due To Affiliate Current And Noncurrent
DueToAffiliateCurrentAndNoncurrent
162500 USD
MCMJ Cover Expenses
CoverExpenses
41458 USD
CY2019Q4 MCMJ Outstanding Promissory Notes
OutstandingPromissoryNotes
16458 USD
CY2020Q3 MCMJ Outstanding Promissory Notes
OutstandingPromissoryNotes
16458 USD
CY2019Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100569 USD
CY2019Q4 MCMJ Office Space Utilities And Secretarial And Administrative Support
OfficeSpaceUtilitiesAndSecretarialAndAdministrativeSupport
5000 USD
CY2020Q3 us-gaap Professional Fees
ProfessionalFees
15000 USD
us-gaap Professional Fees
ProfessionalFees
35000 USD
MCMJ Servicing Fee
ServicingFee
5000 USD
CY2019Q4 us-gaap Accrued Liabilities Fair Value Disclosure
AccruedLiabilitiesFairValueDisclosure
10000 USD
CY2020Q3 MCMJ Gross Proceeds Percentage
GrossProceedsPercentage
0.035 pure
CY2020Q3 MCMJ Common Stock Subject To Possible Redemption Share
CommonStockSubjectToPossibleRedemptionShare
12537714 shares
CY2019Q4 MCMJ Common Stock Subject To Possible Redemption Share
CommonStockSubjectToPossibleRedemptionShare
12550477 shares
us-gaap Business Combination Control Obtained Description
BusinessCombinationControlObtainedDescription
initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company's board of directors, and in the case of any such issuance to the Sponsor, initial stockholders or their affiliates, without taking into account any Founder's Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of an initial Business Combination on the date of the consummation of an initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummated an initial Business Combination (such price, the "Market Value") is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities.

Files In Submission

Name View Source Status
0001213900-20-037061-index-headers.html Edgar Link pending
0001213900-20-037061-index.html Edgar Link pending
0001213900-20-037061.txt Edgar Link pending
0001213900-20-037061-xbrl.zip Edgar Link pending
f10q0920ex31_meridamerger.htm Edgar Link pending
f10q0920ex32_meridamerger.htm Edgar Link pending
f10q0920_meridamergercorp1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcmj-20200930.xml Edgar Link completed
mcmj-20200930.xsd Edgar Link pending
mcmj-20200930_cal.xml Edgar Link unprocessable
mcmj-20200930_def.xml Edgar Link unprocessable
mcmj-20200930_lab.xml Edgar Link unprocessable
mcmj-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending